<span item_type="fundamental" item_id="d4e9a7af950466fe9a0747cb567feca3" counter_id="ST/US/BTSGU" env="prod"></span><span item_type="announcement" item_id="511602624077829889" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 2.878 B.</p><p>EPS: As of FY2025 Q1, the actual value is USD 0.14.</p><p>EBIT: As of FY2025 Q1, the actual value is USD 91.57 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Pharmacy Solutions Revenue</strong>: $2,532 million, up 28% from $1,977 million in the first quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000095017025062245/btsg-ex99_1.htm"></span></li><li><strong>Provider Services Revenue</strong>: $346 million, up 12% from $309 million in the first quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000095017025062245/btsg-ex99_1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Income from Continuing Operations</strong>: $9.2 million, compared to a Net Loss of $56.0 million in the first quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000095017025062245/btsg-ex99_1.htm"></span></li><li><strong>Gross Profit</strong>: $338 million, up 15.7% from $292 million in the first quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000095017025062245/btsg-ex99_1.htm"></span></li><li><strong>Operating Income</strong>: $50.7 million, compared to an Operating Loss of - $15.3 million in the first quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000095017025062245/btsg-ex99_1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Provided by Operating Activities</strong>: $101.6 million, compared to - $78.9 million in the first quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000095017025062245/btsg-ex99_1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Adjusted EBITDA</strong>: $131 million, up 28.2% from $102 million in the first quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000095017025062245/btsg-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><p>BrightSpring Health Services has increased its full-year 2025 guidance, projecting net revenue between $12,000 million and $12,500 million, and Adjusted EBITDA between $570 million and $585 million. The Pharmacy Segment Revenue is expected to grow between 20.5% and 25.7%, while the Provider Segment Revenue is anticipated to increase between 10.0% and 13.8%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1865782/000095017025062245/btsg-ex99_1.htm"></span></p>

BrightSpring Health Services - Unit | 8-K: FY2025 Q1 Revenue: USD 2.878 B